---
title: "Top Executive Makes Bold Insider Move at Lineage Therap"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278988939.md"
description: "Lineage Therap's CEO, Brian Culley, purchased 15,000 shares valued at $24,300, indicating strong confidence in the company. The stock has been influenced by the Q4 earnings call, which revealed an extended cash runway into 2028 and revenue growth, but analysts express concerns over high operating losses and cash burn. TipRanks’ AI Analyst rates LCTX as Neutral due to these challenges, despite positive factors like low leverage and an extended cash runway. Current market cap stands at $418.5M with a YTD price performance of 0.60%."
datetime: "2026-03-13T02:11:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278988939.md)
  - [en](https://longbridge.com/en/news/278988939.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278988939.md)
---

# Top Executive Makes Bold Insider Move at Lineage Therap

New insider activity at Lineage Therap ( (LCTX) ) has taken place on March 12, 2026.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Lineage Therap’s President and CEO, Brian Culley, has demonstrated confidence in the company by purchasing 15,000 shares of Lineage Therap stock in a recent insider transaction. The buy is valued at $24,300, signaling a notable personal investment by the company’s top executive.

**Recent Updates on LCTX stock**

Lineage Cell Therapeutics shares have been reacting to its Q4 earnings call, where management highlighted a much-extended cash runway into 2028, strong collaboration-driven revenue growth, and multiple technical milestones that de-risk its AlloSCOPE cell therapy platform and OpRegen partnership with Roche/Genentech. At the same time, analysts are weighing higher operating and R&D spending, large noncash-driven net losses, dependence on partners for key timelines, new regulatory and supply-chain risks tied to historical cell lines, and remaining uncertainties in scaling its islet cell manufacturing, all of which factor into recent reassessments of valuation and price targets.

**Spark’s Take on LCTX Stock**

According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.

The score is held back primarily by heavy operating losses and sustained cash burn despite improving revenue. Offsetting factors include an extended cash runway into Q2 2028 and low leverage, while technicals are mixed with the stock below key short/medium-term moving averages. Valuation is difficult to support given negative earnings and no dividend data.

To see Spark’s full report on LCTX stock, click here.

**More about Lineage Therap**

**YTD Price Performance:** 0.60%

**Average Trading Volume:** 1,193,482

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $418.5M

### Related Stocks

- [LCTX.US](https://longbridge.com/en/quote/LCTX.US.md)

## Related News & Research

- [Lineage Therap Expands ATM Equity Offering Capacity](https://longbridge.com/en/news/278736148.md)
- [This Analyst Just Cut Zscaler Stock to 'Neutral.' Here's Why.](https://longbridge.com/en/news/282353147.md)
- [ServiceNow's Moat Weaker Amid Rising AI Risks, UBS Says](https://longbridge.com/en/news/282365576.md)
- [ServiceNow AI pricing change takes on enterprise ROI struggles](https://longbridge.com/en/news/282378022.md)
- [This Artificial Intelligence (AI) Stock Just Hit an All-Time Low, But Wall Street Says It's Time to Buy](https://longbridge.com/en/news/282512108.md)